MétaCan
Menu
← Back to cohort
Record W1741007114 · doi:10.5489/cuaj.1175

Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists

2013· article· en· W1741007114 on OpenAlexaffvenueabout
D.A. Loblaw, Tom Pickles, Patrick Cheung, Himu Lukka, Sergio Faria, Laurence Klotz

Bibliographic record

VenueCanadian Urological Association Journal · 2013
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Diagnosis and Treatment
Canadian institutionsMcGill UniversityMontreal General HospitalBC Cancer AgencyHealth Sciences CentreJuravinski Cancer CentreSunnybrook Health Science Centre
FundersSanofiAstraZenecaAbbott Laboratories
KeywordsMedicineProstate cancerAsymptomaticRadiation therapyAndrogen deprivation therapyProstate-specific antigenRadiation oncologyClinical trialOncologyInternal medicineDoubling timeHormone therapyUrologyCancer

Abstract

fetched live from OpenAlex

Introduction: A survey of Canadian uro-oncology specialists wasperformed to assess practice patterns of patients with recurrentprostate cancer postradiotherapy and to assess the feasibility ofconducting a trial in this setting.Methods: There were 14 survey questions and 1 demographic question.Responses were reported by frequency.Results: There were 96 respondents. Most respondents use bothprostate-specific antigen doubling time (PSAdt) and PSA levelwhen deciding to start androgen deprivation therapy (ADT) inasymptomatic patients. About half of respondents start ADT whenPSA is greater than 10 ng/mL or when the PSAdt is less than6 months. Eighty-six percent felt that the timing of ADT was animportant research question. Over 1500 patients per year wereestimated as being available for such a trial.Conclusion: After radiotherapy failure, respondents initiated ADTabout half of the time when PSA is less than 10 ng/mL and/orPSAdt is less than 6 months. A clinical trial examining the timingof ADT has strong support and appears to be feasible.Introduction : Un sondage mené auprès d’uro-oncologues cana diensa été mené afin d’évaluer les tendances concernant le traitement depatients atteints de cancer récurrent de la prostate après une radiothérapieet d’évaluer la faisabilité d’une étude dans ce contexte.Méthodologie : Le sondage comportait 14 questions portant sur lestraitements et 1 question de type démographique. Les réponsesétaient groupées par fréquence.Résultats : Quatre-vingt-seize médecins ont participé au sondage.La majorité des répondants se basent sur le temps de doublementde l’APS et les taux d’APS pour décider du moment optimal pouramorcer un traitement antiandrogène chez les patients asymptomatiques.Environ la moitié des répondants entreprennent un traitementantiandrogène lorsque le taux d’APS dépasse 10 ng/mL oulorsque le temps de doublement de l’APS est inférieur à 6 mois.Quatre-vingt-six pour cent des répondants ont indiqué que le momentoptimal pour l’amorce du traitement antiandrogène représentaitune importante question de recherche. On estime que plus de1500 patients par année seraient admissibles à une telle étude.Conclusion : Après l’échec d’une radiothérapie, les répondants entreprennentun traitement antiandrogène dans environ la moitié descas lorsque l’APS est inférieur à 10 ng/mL et/ou lorsque le tempsde doublement de l’APS est inférieur à 6 mois. Un essai cliniqueportant sur la détermination du moment optimal pour l’amorce dutraitement antiandrogène est fortement souhaité et semble faisable.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.063
Threshold uncertainty score0.127

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.004
Science and technology studies0.0010.001
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.023
GPT teacher head0.248
Teacher spread0.224 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2013
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Urological Association Journal→Same topicProstate Cancer Diagnosis and Treatment→French-language works237,207→